<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300920</url>
  </required_header>
  <id_info>
    <org_study_id>19-12021232</org_study_id>
    <secondary_id>1U24HL145265-01A1</secondary_id>
    <nct_id>NCT04300920</nct_id>
  </id_info>
  <brief_title>Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial</brief_title>
  <acronym>PRECISIONS</acronym>
  <official_title>Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pulmonary Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Three Lakes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard
      care with matched placebo plus standard of care in patients diagnosed with idiopathic
      pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare
      the time to a composite endpoint of relative decline in lung function [10% relative decline
      in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or
      all-cause mortality]

      The secondary objectives will be to examine the effect of NAC on the components of the
      primary composite endpoint, the rates of clinical events, change in physiology, change in
      health status, and change in respiratory symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled trial of NAC or placebo
      in about 200 participants with IPF with a TOLLIP rs3750920 TT genotype.

      Eligible participants will be randomized in a 1:1 fashion to NAC or placebo, stratified by
      stable concomitant IPF therapy use (i.e., pirfenidone or nintedanib administered for at least
      6 weeks prior to screening) versus no pirfenidone or nintedanib use. Participants will
      receive 600 mg NAC orally or matched placebo to take three times daily for 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible participants will be randomized in a 1:1 fashion to NAC or placebo, stratified by stable concomitant IPF therapy use (i.e., pirfenidone or nintedanib administered for at least 6 weeks prior to screening) versus no pirfenidone or nintedanib use. Participants will receive 600 mg NAC orally three times daily or matched placebo for 24 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant and site personnel will not know which study treatment the participant is receiving.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to one of the following composite endpoint criteria: 10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplant or death from any cause.</measure>
    <time_frame>24 months</time_frame>
    <description>This is a composite endpoint of time to 10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplant or death from any cause. Respiratory hospitalizations will be determined by a blinded clinical events classification (adjudication) committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to one of the following composite criteria: 10% relative decline in FVC % predicted, first respiratory hospitalization, lung transplant or death from any cause.</measure>
    <time_frame>24 months</time_frame>
    <description>This is a composite endpoint of time to 10% relative decline in FVC % predicted, first respiratory hospitalization, lung transplant or death from any cause. Respiratory hospitalizations will be determined by a blinded clinical events classification (adjudication) committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death from any cause</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first respiratory hospitalization</measure>
    <time_frame>24 months</time_frame>
    <description>Respiratory hospitalizations will be determined by a blinded clinical events classification (adjudication) committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 10% relative decline in FVC</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to lung transplant</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 10% relative decline in FVC %predicted</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first all-cause hospitalization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of respiratory hospitalizations</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of non-elective, all-cause hospitalizations</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants undergoing lung transplant during follow-up</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC from randomization at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC % predicted from randomization at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC % predicted from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diffusing capacity of the lung for carbon monoxide (DLCO) corrected for hemoglobin from randomization at 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DLCO from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the Leicester Cough Questionnaire (LCQ) from randomization at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the EuroQoL EQ-5D Questionnaire from randomization at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the University of California, San Diego Shortness of Breath (UCSD-SOB) Questionnaire from randomization at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire from randomization at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the St. George's Respiratory Questionnaire (SGRQ) from randomization at 12 months.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the Leicester Cough Questionnaire (LCQ) from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the EuroQoL EQ-5D Questionnaire from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the University of California, San Diego Shortness of Breath (UCSD-SOB) Questionnaire from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported outcomes scores for the St. George's Respiratory Questionnaire (SGRQ) from randomization at 24 months</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with and number of treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, and unanticipated problems</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg oral N-acetylcysteine (NAC) three times daily for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet three times daily for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl cysteine</intervention_name>
    <description>600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral placebo tablet three times daily for 24 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 40 years of age

          -  Diagnosed with IPF according to 2018 ATS/ERS/JRS/ALAT, confirmed by enrolling
             investigator

          -  Signed informed consent

          -  If taking pirfenidone or nintedanib, must be on stable dose for at least 6 weeks prior
             to enrollment visit

          -  Confirmed rs3570920 TT TOLLIP genotype

        Exclusion Criteria:

          -  Pregnancy or planning to become pregnant

          -  Women of childbearing potential not willing to remain abstinent (refrain from
             heterosexual intercourse) or use two adequate methods of contraception, including at
             least one method with a failure rate of &lt;1% per year during study participation

          -  Significant medical, surgical or psychiatric illness that in the opinion of the
             investigator would affect subject safety, including liver and renal failure

          -  Receipt of an investigational drug or biological agent within the previous 4 weeks of
             the screening visit or 5 times the half-life, if longer

          -  Supplemental or prescribed NAC therapy within 60 days of enrollment

          -  Listed for lung transplantation at the time of screening

          -  History of lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Imre Noth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Flaherty, MS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cathie Spino, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betsy Peters</last_name>
    <phone>646-962-2742</phone>
    <email>elp2018@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Joshua Mooney, MD, MS</last_name>
      <phone>650-725-9729</phone>
      <email>jmooney1@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Jacobs, RN, MS</last_name>
      <phone>650-735-8083</phone>
      <email>ssjpulm@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amy Case, MD</last_name>
      <phone>770-948-6041</phone>
      <email>amy.case@piedmont.org</email>
    </contact>
    <contact_backup>
      <last_name>Stacy Beasley</last_name>
      <phone>770-745-1404</phone>
      <email>Stacy.Beasley@piedmont.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Belloli, MD</last_name>
      <phone>734-647-6477</phone>
      <email>bellolie@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Candace Flaherty</last_name>
      <email>cflah@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Kottman, MD</last_name>
      <phone>585-275-4861</phone>
      <email>matt_kottmann@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Clark, LPN</last_name>
      <phone>585-397-6516</phone>
      <email>karen_clark@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerard Criner, MD</last_name>
      <phone>215-707-8113</phone>
      <email>Gerard.Criner@tuhs.temple.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francis McGonagle</last_name>
      <phone>215-707-2682</phone>
      <email>Francine.McGonagle@tuhs.temple.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Timothy M Whelan, MD</last_name>
      <phone>843-792-1414</phone>
      <email>whelant@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ashley Warden</last_name>
      <email>jonesash@musc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IPF</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>n-acetylcysteine</keyword>
  <keyword>NAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The de-identified analytic data will be prepared as SAS transport files or ASCII comma-delimited files with accompanying codebooks that describe the data and data structure. The redaction will employ best practices and will be consistent with NHLBI data sharing policies.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>3 years after the end of the study or 2 years after the main paper reporting the results of the trial, whichever comes first.</ipd_time_frame>
    <ipd_access_criteria>Data will be shared through the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

